Journal
CELL METABOLISM
Volume 10, Issue 6, Pages 491-498Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2009.09.007
Keywords
-
Categories
Funding
- National Institutes of Health [CA65861, DK80756]
- American Diabetes Association [7-07-RA-80]
- NIDDK Diabetes and Endocrinology Research Center [DK52530]
Ask authors/readers for more resources
Nonalcoholic steatosis (fatty liver) is a major cause of liver dysfunction that is associated with insulin resistance and metabolic syndrome. The cJun NH2-terminal kinase 1 (JNK1) signaling pathway is implicated in the pathogenesis of hepatic steatosis and drugs that target JNK1 may be useful for treatment of this disease. Indeed, mice with defects in expression in adipose tissue are protected against hepatic steatosis. Here we report that mice with specific ablation of Jnk1 in hepatocytes exhibit glucose intolerance, insulin resistance, and hepatic steatosis. JNK1 therefore serves opposing actions in liver and adipose tissue to both promote and prevent hepatic steatosis. This finding has potential implications for the design of JNK1-selective drugs for the treatment of metabolic syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available